Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23668711 | 0.85 | MAPT (0.42) | MAPTHPGDLMNAALOX15TSHR | |
| SCHEMBL21883075 | 0.82 | MAPT (0.43) | MAPTHPGDLMNAALOX15TSHR | |
| SCHEMBL23037565 | 0.78 | PABPC1 (0.43) | MAPTHPGDLMNAALOX15TSHR | |
| SCHEMBL25992599 | 0.76 | MEN1 (0.46) | MAPTHPGDLMNAALOX15TSHR | |
| SCHEMBL14465482 | 0.76 | DHFR (0.48) | MAPTHPGDLMNAALOX15TSHR | |
| SCHEMBL23037539 | 0.75 | NCF1 (0.43) | MAPTHPGDLMNAALOX15TSHR | |
| SCHEMBL23108693 | 0.75 | GPR3 (0.59) | MAPTHPGDLMNAALOX15TSHR | |
| SCHEMBL6640636 | 0.73 | METAP2 (0.47) | KDM4ECRHR1MEN1KMT2AMETAP2 | |
| SCHEMBL23037533 | 0.73 | NPC1 (0.36) | MAPTHPGDLMNAALOX15TSHR | |
| SCHEMBL23037549 | 0.73 | MAPT (0.59) | MAPTHPGDLMNAALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371417-B2 | Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties | Universite Paris-Saclay (FR) | 2025-07-29 | — | — | US | disclosed |
| US-20230203005-A1 | COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES | Universite Paris-Saclay (FR) | 2023-06-29 | — | — | US | disclosed |
| US-20230203005-A1 | COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES | Universite Paris-Saclay (FR) | 2023-06-29 | — | — | US | disclosed |
| US-20230203005-A1 | COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES | Universite Paris-Saclay (FR) | 2023-06-29 | — | — | US | disclosed |
| US-11634405-B2 | Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties | UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE (FR) | 2023-04-25 | — | — | US | disclosed |
| US-11634405-B2 | Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties | UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE (FR) | 2023-04-25 | — | — | US | disclosed |
| US-20210230140-A1 | COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES | Universite Paris-Saclay (FR) | 2021-07-29 | — | — | US | disclosed |
| US-20210230140-A1 | COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES | Universite Paris-Saclay (FR) | 2021-07-29 | — | — | US | disclosed |
| EP-3784662-A1 | COMPOUNDS HAVING A TUBULIN-POLYMERISATION-INHIBITING ACTIVITY AND IMMUNOMODULATORY PROPERTIES | Université Paris-Saclay (FR) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371417-B2 | Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties | TUBB1, TUBB, TUBB3 | MAPT 34/4885HPGD 2890/4885LMNA 3653/4885 |
| US-11634405-B2 | Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties | TUBB1, TUBB, TUBB3 | MAPT 34/4885HPGD 2890/4885LMNA 3653/4885 |
| US-20230203005-A1 | COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES | TUBB1, TUBB, TUBB3 | MAPT 34/4885HPGD 2890/4885LMNA 3653/4885 |
| US-20210230140-A1 | COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES | TUBB1, TUBB, TUBB3 | MAPT 34/4885HPGD 2890/4885LMNA 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.